Loading
Receptors, Pattern Recognition / Viral Infections / DNA Viruses · Journal article
Human Vaccines & Immunotherapeutics · August 5, 2026
A consensus or society position rather than new primary data.
This is a narrative review comparing innate immune mechanisms across representative RNA viruses (influenza, SARS-CoV-2, HIV) and DNA viruses (HSV, HBV, CMV), structured around viral recognition, signaling, immune evasion, and therapeutic targets. The authors acknowledge that comparisons are limited to medically important representatives and should not be interpreted as universally applicable to all RNA or DNA viruses.
Narrative review article. Patients infected with major RNA viruses (influenza, SARS-CoV-2, HIV) or DNA viruses (HSV, HBV, CMV); review scope limited to representative medically important viruses.
RNA viruses generally trigger rapid interferon responses through RIG-I- and TLR-mediated signaling, whereas DNA viruses employ diverse strategies to modulate cytosolic DNA sensing pathways Dysregulated or excessive innate immune activation may result in immunopathology, including cytokine storm syndromes observed in severe influenza and COVID-19 Chronic viral infections such as HIV and HBV are characterized by persistent immune activation and progressive dysfunction of innate immune cells
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a conceptual framework for understanding mechanistic differences in innate immunity across RNA and DNA viral infections, which may inform design of broad-spectrum antiviral and immunomodulatory therapies. However, as a qualitative synthesis without empirical comparison or outcome data, it should be used to contextualize rather than direct clinical decision-making.
This is a comprehensive review article synthesizing mechanistic knowledge of innate immune responses across major RNA and DNA viruses, intended to inform therapeutic strategy development rather than report new empirical findings.
As stated by the source record.
This review provides a conceptual framework for understanding mechanistic differences in innate immunity across RNA and DNA viral infections, which may inform design of broad-spectrum antiviral and immunomodulatory therapies. However, as a qualitative synthesis without empirical comparison or outcome data, it should be used to contextualize rather than direct clinical decision-making.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Innate immunity is the first defense against viral infections, limiting viral replication and initiating adaptive immunity. Viral pathogens are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), (RIG-I-like receptors) RLRs, and the (cyclic GMP-AMP synthase) cGAS-STING pathway, which trigger interferon production and antiviral responses. This review compares innate immune responses to major RNA viruses (influenza, SARS-CoV-2, HIV) and DNA viruses (HSV, HBV, CMV). While these viruses activate similar pathways, they differ in interferon dynamics, inflammatory responses, immune cell activation, and immune evasion mechanisms. RNA viruses often induce rapid and strong innate responses, whereas many DNA viruses establish persistence through immune modulation. Dysregulated innate immunity can contribute to cytokine storms, chronic inflammation, and tissue damage. Therapeutic strategies targeting innate immunity, such as interferons, cytokine inhibitors, PRR agonists, and host-directed antivirals, may improve outcomes. Infection severity depends on the timing, magnitude, and regulation of innate immune responses.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.